Sanghoon Lee, Ph.D., M.S.

Peer-Reviewed Articles

1. Brodsky AL, Asare A, Fellman B, Anderson K, Yao J, Lee S, Tran H, Xu X, Liu J, Celestino J, Hajek RA, Morgan MB, Mohammad M, Soliman P, Shafer A, Sood AK, Bodurka D, Fleming ND, Onstad Grinsfelder M, Milojevic L, Jazaeri AA, Mills GB, Coleman RL, Westin SN. Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. Clin Cancer Res, 2026. e-Pub 2026. PMID: 41528970.
2. Tarney CM, Mhawech-Fauceglia P, Ogata JD, Oliver J, Abulez T, Branton PA, Movahedi-Lankarani S, Hood BL, Conrads KA, Rosalik K, Wong KK, Gershenson DM, Lee S, Sood AK, Bast RC Jr, Darcy KM, Phippen NT, Maxwell GL, Conrads TP, Bateman NW. Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers. Clin Proteomics 22(1):33, 2025. e-Pub 2025. PMID: 41053579.
3. Hou J, Ju CW, Egan NA, Wei Y, Wang Y, Dang M, Zhou T, Shi L, Zheng N, Chen S, Guerrero AM, Liang X, Wu W, Akhtar A, Dhiman C, Roy Burman D, Gerges AE, Flores MD, Li H, Zhang LS, Kok M, Mao X, Wang L, Feng Q, Chen Y, Lee S, McGrail DJ, Sahni N, He C, Jazaeri AA, Peng W. Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer. Adv Sci (Weinh):e07718, 2025. e-Pub 2025. PMID: 41042068.
4. Bayraktar E, Rodriguez-Aguayo C, Stur E, Kumar S, Mangala LS, Jennings NB, Bayram NN, Corvigno S, Asare A, Ivan C, Kim MS, Vu TC, Hanjra P, Kim S, Ahumada AL, Wu W, Lee S, Szymanowska A, Oztatlici H, Estecio MR, Lee JS, Jain AK, Sahni N, Hagan JP, Baylin S, Liu J, Lopez-Berestein G, Pradeep S, Sood AK. Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. Cell Rep Med 6(9):102329, 2025. e-Pub 2025. PMID: 40907495.
5. Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities. Clin Cancer Res 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
6. Dai Y, Knisely A, Yano M, Dang M, Hinchcliff EM, Lee S, Welp A, Chelvanambi M, Lastrapes M, Liu H, Yuan Z, Wang C, Nie H, Jean S, Montaner LJ, Hou J, Patel A, Patel S, Fellman B, Yuan Y, Sun B, Pandurengan RK, Cuentas ERP, Celestino J, Liu Y, Liu J, Hillman RT, Westin SN, Sood AK, Soliman PT, Shafer A, Meyer LA, Gershenson DM, Vining D, Ganeshan D, Lu K, Wargo JA, Peng W, Zhang R, Wang L, Jazaeri AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
7. Stur, E, Peng, F, Teng, PN, Bayraktar, E, Hu, M, Corvigno, S, Brown, DJ, Lee, S, Moore, KN, Bateman, NW, Darcy, KM, Maxwell, GL, P. Conrads, T, Sahni, N, Vázquez-García, I, Shah, S, Celestino, J, D. Fleming, N, Navin, N, Wang, L, Sood, AK. The dynamic immune behavior of primary and metastatic ovarian carcinoma. NPJ Precis Oncol 9(1):120, 2025. e-Pub 2025. PMID: 40281242.
8. Corvigno, S, Yao, J, Asare, A, Zhao, L, Celestino, J, Hajek, RA, Goette, EA, Rogers, RT, Montoya, RN, Song, P, Zhang, Q, Song, X, Mohammad, MM, Shaw, KR, Zhang, J, Lu, KH, Jazaeri, AA, Westin, SN, Sood, AK, Lee, S. Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Frontiers in Oncology 15, 2025. e-Pub 2025. PMID: 40365343.
9. Guo S, Liu X, Cheng X, Jiang Y, Ji S, Liang Q, Koval A, Li Y, Owen LA, Kim IK, Aparicio A, Lee S, Sood AK, Kopetz S, Shen JP, Weinstein JN, DeAngelis MM, Chen R, Wang W. A deconvolution framework that uses single-cell sequencing plus a small benchmark data set for accurate analysis of cell type ratios in complex tissue samples. Genome Res 35(1):147-161, 2025. e-Pub 2025. PMID: 39586714.
10. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med 6(1):100494, 2025. e-Pub 2025. PMID: 39151421.
11. Westin SN, Stur E, Fellman BM, Conrads TP, Abulez T, Chu Y, Batman NW, Lee S, Hajek RA, Celestino J, Lu Z, Yuan Y, Tran H, conrads KA, Hood BL, Soliman PT, Fleming ND, Cobb L, Shafer A, Taylor J, Jazaeri AA, Frumovitz MM, Rmirrez PT, Meyer LA Alvarado T, Hull S, Liu J, Lu KH, Mills GB, Wang L, Maxwell GL, Coleman RLm Sood AK. Molecular markers of response to of ENzalutamide in combination with PAClitaxel in a phase II trial for advanced or recurrent endometrioid endometrial adenocarcinoma (ENPAC). e-Pub 2025.
12. Cobb LP, Dai Y, Ayala MM, Lermi NO, Hernandez SD, Davis J, Lee S, Lawson BC, Hajek RA, Celestino J, Liu J, Wang L, Solis Soto LM, Haymaker C, Chen K, Jiang M, Lu W, Sanchez B, Sara Hull MD, Vining D, Fellman B, Yuan Y, Westin SN, Taylor J, Bevers M, Shafer A, Fleming ND, Lu KH, Gershenson DM, Jazaeri AA. A Pilot Phase II Study of Neoadjuvant Fulvestrant plus Abemaciclib in Women with Advanced Low-Grade Serous Carcinoma. e-Pub 2025.
13. Kim MS, Glassman D, Handley KF, Lankenau Ahumada A, Jennings NB, Bayraktar E, Foster K, Joseph R, Lee S, Coleman RL, Sood AK. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med 13(15):e70031, 2024. e-Pub 2024. PMID: 39114948.
14. Corvigno S, Liu Y, Bayraktar E, Stur E, Bayram NN, Ahumada AL, Nagaraju S, Rodriguez-Aguayo C, Chen H, Vu TC, Wen Y, Liang H, Zhao L, Lee S, Lopez-Berestein G, Sood AK. Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy. NPJ Precis Oncol 8(1):86, 2024. e-Pub 2024. PMID: 38582949.
15. Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 115(1):115, 2023. e-Pub 2023. PMID: 37923835.
16. Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming Ovarian Cancer Care by Targeting Minimal Residual Disease. Med 4(11):750-760, 2023. e-Pub 2023. PMID: 37951209.
17. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129(11):1672-1680, 2023. e-Pub 2023. PMID: 36930815.
18. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience 26(2):106020, 2023. e-Pub 2023. PMID: 36824283.
19. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
20. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
21. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clin Cancer Res 28(17):3669-3676, 2022. e-Pub 2022. PMID: 35736816.
22. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer. Cancers (Basel) 14(15):3589, 2022. e-Pub 2022. PMID: 35892848.
23. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer 8(1):64, 2022. e-Pub 2022. PMID: 35538088.
24. Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AK. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel) 14(6), 2022. e-Pub 2022. PMID: 35326647.
25. Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience 25(3):103923, 2022. e-Pub 2022. PMID: 35252817.
26. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clin Cancer Res 27(23):6345, 2021. e-Pub 2021. PMID: 34518313.
27. Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep 36(7):109549, 2021. e-Pub 2021. PMID: 34407412.
28. Lobo de Figueiredo-Pontes L, Adamcova MK, Grusanovic S, Kuzmina M, Aparecida Lopes I, Fernandes de Oliveira Costa A, Zhang H, Strnad H, Lee S, Moudra A, Jonasova AT, Zidka M, Welner RS, Tenen DG, Alberich-Jorda M. Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon gamma. Stem Cell Reports 16(8):1999-2013, 2021. e-Pub 2021. PMID: 34242616.
29. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33572451.
30. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-Function p53 Protein Transferred via Small Extracellular Vesicles Promotes Conversion of Fibroblasts to a Cancer-Associated Phenotype. Cell Rep 34(6):108726, 2021. e-Pub 2021. PMID: 33567287.
31. Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience 24(2):102053, 2021. e-Pub 2021. PMID: 33537658.
32. Zhou Q, Yu M, Tirado-Magallanes R, Li B, Kong L, Guo M, Tan ZH, Lee S, Chai L, Numata A, Benoukraf T, Fullwood MJ, Osato M, Ren B, Tenen DG. ZNF143 mediates CTCF-bound promoter-enhancer loops required for murine hematopoietic stem and progenitor cell function. Nat Commun 12(1):43, 2021. e-Pub 2021. PMID: 33397967.
33. Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. Mol Cancer Ther 19(11):2396, 2020. e-Pub 2020. PMID: 32943548.
34. Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget 11(32):3035-3047, 2020. e-Pub 2020. PMID: 32850008.
35. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer. Cell Rep 31(2):107502, 2020. e-Pub 2020. PMID: 32294438.
36. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol 155(3):420, 2019. e-Pub 2019. PMID: 31623857.
37. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell 35(6):851-867, 2019. e-Pub 2019. PMID: 31185210.
38. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 10(37):3533-3546, 2019. e-Pub 2019. PMID: 31191824.
39. Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology 8(1):e1512455, 2018. e-Pub 2018. PMID: 30546948.
40. Kardosova M, Zjablovskaja P, Danek P, Angelisova P, de Figueiredo-Pontes LL, Welner RS, Brdicka T, Lee S, Tenen DG, Alberich-Jorda M. C/EBPγ is dispensable for steady-state and emergency granulopoiesis. Haematologica 103(8):e331-e335, 2018. e-Pub 2018. PMID: 29567783.
41. Lee S, Shah T, Yin C, Hochberg J, Ayello J, Morris E, van de Ven C, Cairo MS. Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. Oncotarget 9(11):9776-9788, 2018. e-Pub 2018. PMID: 29515770.
42. Lee S, Day NS, Miles RR, Perkins SL, Lim MS, Ayello J, van de Ven C, Harrison L, El-Mallawany NK, Goldman S, Cairo MS. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol 177(4):601-611, 2017. e-Pub 2017. PMID: 28474336.
43. Lee S, Luo W, Shah T, Yin C, O'Connell T, Chung TH, Perkins SL, Miles RR, Ayello J, Morris E, Harrison L, van de Ven C, Cairo MS. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. Oncotarget 8(17):27839-27853, 2017. e-Pub 2017. PMID: 28427156.
44. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368(24):2266-76, 2013. e-Pub 2013. PMID: 23758232.
45. Staber PB, Zhang P, Ye M, Welner RS, Nombela-Arrieta C, Bach C, Kerenyi M, Bartholdy BA, Zhang H, Alberich-Jordà M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Orkin SH, Göttgens B, Rosenbauer F, Huang G, Tenen DG. Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol Cell 49(5):934-46, 2013. e-Pub 2013. PMID: 23395001.
46. Levantini E, Lee S, Radomska HS, Hetherington CJ, Alberich-Jorda M, Amabile G, Zhang P, Gonzalez DA, Zhang J, Basseres DS, Wilson NK, Koschmieder S, Huang G, Zhang DE, Ebralidze AK, Bonifer C, Okuno Y, Gottgens B, Tenen DG. RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element. EMBO J 30(19):4059-70, 2011. e-Pub 2011. PMID: 21873977.
47. Zhou YD, Lee S, Jin Z, Wright M, Smith SE, Anderson MP. Arrested Maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat Med 15(10):1208-1214, 2009. e-Pub 2009. PMID: 19701204.
48. Ebralidze AK, Guibal FC, Steidl U, Zhang P, Lee S, Bartholdy B, Jorda MA, Petkova V, Rosenbauer F, Huang G, Dayaram T, Klupp J, O'Brien KB, Will B, Hoogenkamp M, Borden KL, Bonifer C, Tenen DG. PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev 22(15):2085-2092, 2008. e-Pub 2008. PMID: 18676813.
49. Lee S, Huang H, Niu Y, Tommasino M, Lenoir G, Sylla BS. Dok1 expression and mutation in Burkitt's lymphoma cell lines. Cancer Lett 245(1-2):44-50, 2007. e-Pub 2007. PMID: 16338067.
50. Lee S, Andrieu C, Saltel F, Destaing O, Auclair J, Pouchkine V, Michelon J, Salaun B, Kobayashi R, Jurdic P, Kieff ED, Sylla BS. IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation. Proc Natl Acad Sci U S A 101(50):17416-21, 2004. e-Pub 2004. PMID: 15574499.
51. Lee S, Roy F, Galmarini CM, Accardi R, Michelon J, Viller A, Cros E, Dumontet C, Sylla BS. Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene 23(13):2287-97, 2004. e-Pub 2004. PMID: 14730347.
52. Sang BC, Ryoo SH, Lee S. Analysis of Sequence on Promoter of κ-casein Genes in Korean Native Cattle and Holstein. Korean J of Agric Sci 27(1):33-38, 2000. e-Pub 2000.
53. Yoo SL, Sang SC, Ryoo SH, Lee S, Lee TH, Yu DY. Sequence Analysis of β-lactoglobulin Promoter in Korean Cattle. J Anim Sci Technol 42(4):443-450, 2000. e-Pub 2000.
54. Lee S, Sang AB. Association Traits with Bovine Leukemia Virus Resistance in Holstein and Korean Cattle. Korean J of Agric Sci 27(2):101-106, 2000. e-Pub 2000.
55. Lee S, Lee CS, Lee KY, Park TS, Han JY, Kim SK, Sang BC. Association of Microsatellite Polymorphisms of BoLA-DRB3 intron2 with Economic Traits in Holstein and Korean Cattle. J Anim Sci Technol 42(6):757-766, 2000. e-Pub 2000.
56. Sang BC, Kim JA, Lee S, Seo GW, Han SW. Characteristics of αs2-casein Gene using PCR Technique in Korean Native Goat. J Anim Sci Technol 42(4):433-442, 2000. e-Pub 2000.
57. Lee S, Seo KW, Kwon I, Sung CK, Kim SK, Sang BC. Analysis of Genetic Polymorphisms and Similarity using Random Amplified Polymorphic DNAs in Cattle. Korean J Agric Sci 26(2):39-48, 1999. e-Pub 1999.
58. Sang BC, Lee S, Ryoo SH, Seo GW, Han SW, Kim SK. Identification of Korean Native Goat Meat using DNA analysis. CNU J Agric Sci 26(2):33-38, 1999. e-Pub 1999.
59. Kang HB, Ryoo SH, Lee S, Jeon BS, Sang BC. Characterization of Bovine Lymphocyte Antigen DRB3 exon2 Gene of Korean Native Cattle. Korean J of Agric Sci 25(1):79-88, 1998. e-Pub 1998.
60. Jin HJ, Lee HK, Kim CI, Son DS, Lee S, Cho CY, Han KJ, Na SH, Park BH. The Effects of Specific Genetic Marker on the Quantitative Traits in Holstein Bulls. R.D.A. J. of Livestock Sci 40(1):13, 1998. e-Pub 1998.
61. Sang BC, Ryoo SH, Lee S, Song CE, Nam MS, Jeon BS. Study on the Analysis of β-lactoglobulin and κ-casein genotypes of Cattle using Polymerase Chain Reaction. Korean J of Agric Sci 25(2):216-224, 1998. e-Pub 1998.
62. Sang BC, Han SW, Ryoo SH, Lee S, Kim SK, Shin HD, Kim JH. Association of the Genetic Polymorphism of β-lactoglobulin and κ-casein with Preweaning Body Weights using PCR-RFLP in Korean Cattle. Animal Genetics and Breeding 2(2):125, 1998. e-Pub 1998.
63. Sang BC, Han SW, Shin HD, Ryoo SH, Lee S. Association between Genetic Polymorphism of Blood Protein and Meat Production Traits in Korean Native Cattle. Korean J of Agric Sci 25(1):68-78, 1998. e-Pub 1998.
64. Sang BC, Ryoo SH, Lee S, Han SW, Jeon BS. Association between Genetic Polymorphisms of bloods proteins and Preweaning Body weights in Korean Native Goat. Animal Genetics and Breeding 1(4):251, 1997. e-Pub 1997.
65. Sang BC, Ryoo SH, Lee S, Han SW, Lee CS. Genetic Polymorphisms of Blood Proteins and Enzymes in Korean Native Cattle. Korean J of Agric Sci 22(2):170-179, 1995. e-Pub 1995.
66. Asare A, Corvigno S, Yao J, Fellman B, Michaels V, Nicole DF, Hajek R, Celestino J, Takahashi K, Westin SN, Lee S, Sood AK. Identifying novel factors associated with MDS/AML and PARP inhibitor treatment.
67. Adjei N, Gerber Z, Shen S, Lee S, Zhao L, Yuan Y, Wu J, Hajek R, Celestino J, Liu J, Morgan M, Hull S, Wang X, Sun C, Meyer L, Fleming N, Jazaeri A, Lu K, Zhang J, Futreal P, Sood A, Coleman R, Mills G, Labrie M, Westin AS. N-DUR: Matched paired pharmacodynamics and feasibility phase I/II study of Neoadjuvant DURvalumab with chemotherapy in frontline advanced stage ovarian cancer.

Abstracts

1. Dai Y, Dai E, Liu Y, Pei G, Cho KS, Dang M, Jiang J, Liu Y, Knisely A, Clark H, Lee S, Lubo I, Lu W, Lawson BC, Solis Soto LM, Jazaeri AA, Wang L. A single-cell atlas of ovarian cancer reveals tumor microenvironmental heterogeneity and cancer cell plasticity in response to therapies. J Immunother Cancer 13(Suppl 2):A1421, 2025. e-Pub 2025.
2. A Brodsky, A Asare, J Yao, S Lee, B Fellman, J Liu, R Hajek, M Mohammad, P Soliman, A Shafer, A Sood, D Bodurka, N Fleming, A Jazaeri, G Mills, R Coleman, S Westin. Translational studies of COPANIRA: A phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer. Gynecol Oncol 200(Suppl 1):65, 2025. e-Pub 2025.
3. Asare A, Lee S, Wang L, Sood AK. Epithelial intra-tumoral heterogeneity in ovarian cancer resistance to anti-angiogenesis therapy. Gynecol Oncol 200(Suppl):S10-S11, 2025. e-Pub 2025.
4. Knisely A, Knisely A, Dai Y, Dai Y, Welp A, Welp A, Patel S, Patel S, Fellman B, Fellman B, Lee S, Lee S, How J, How J, Zhang R, Zhang R, Wang L, Wang L, Jazaeri AA, Jazaeri AA. Inactivating PPP2R1A mutations are associated with prolonged survival after Lenvatinib and pembrolizumab treatment in recurrent, microsatellite stable endometrial cancer. Gynecol Oncol 200(Suppl):S36-S37, 2025. e-Pub 2025.
5. Bateman NW, Asare A, Cronin S, Ogata J, Abulez T, Hood BL, Conrads KA, Yao J, Celestino J, Fleming N, Corvigno S, Lee S, Tarney CM, Darcy KM, Phippen N, Conrads TP, Maxwell L, Sood A. Proteome Changes Correlating with Neoadjuvant Chemotherapy Response and Residual Disease in Advanced Ovarian Cancers. American Society on Mass Spectrometry, 2025.
6. Karpinets TV, Wu X, Xu WW, Asare A, Corgvigno S, Celestino J, Hajek RA, Montoya RN, Rogers RT, Kim MS, Soliman PT, Westin SN, Futreal P, Jazaeri AA, Sood AK, Zhang J, Lee S. Intratumoral microbiome profiling using high-depth whole-genome sequencing highlighted Cutibacterium acnes in chemoresistance in ovarian cancer. Cancer Res 85(8_Supplement_1):6520, 2025. e-Pub 2025.
7. Bateman NW, Cronin S, Ogata J, Abulez T, Hood BL, Conrads KA, Asare A, Corvigno S, Lee S, Tarney CM, Darcy KM, Phippen NT, Conrad TP, Maxwell GL, Sood AK. Proteome Alterations Correlating with Neoadjuvant Chemotherapy Response and Residual Disease Status in Advanced Ovarian Cancers. Gynecol Oncol, 2025. e-Pub 2025.
8. Pourebrahim R, Khanna P, Yang D, Muftuoglu M, Ostermann LB, Khazaei S, Zhao R, Asare A, Hajek RA, Lee S, Corvingo S, Gagea M, Sood A, Li R, Takahashi K, Andreeff M. Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA RepairPathway Inhibition with PARP Inhibitors. Blood 144(Supplement 1):726, 2024. e-Pub 2024.
9. Dai Y, Knisely A, Julio I, Lawson B, Lee S, Dai E, Faustino AL, Melendez B, Wani KM, Lu W, Shi O, Chen J, Chelvanambi M, Gibson LA, Johnson SB, Yeh CC, Ingram DR, Hudgens CW, Liu Y, Cho KS, Pei G, Jiang J, Chu Y, Liu Y, Lazar AJ, Gao J, Wargo J, Haymaker C, Soto L, Jazaeri AA, Wang L. The single-cell and spatial immune landscape of ovarian cancer. J Immunother Cancer 12(Suppl 2):847, 2024. e-Pub 2024.
10. Corvigno S, Asare A, Yao J, Zhao L, Fleming ND, Celestino J, Hajek RA, Arboleda Gotte EA, Rogers RT, Lu KH, Jazaeri AA, Westin SN, Sood AK, Lee S. Hidden Threats: Chemotherapy-related clonal Hematopoiesis in patients with ovarian cancer. Gynecol Oncol 190(Supplement 1):S15, 2024. e-Pub 2024.
11. Knisely A, Lee S, Wilke RN, How JA, Fellman B, Scalise CB, Dutta P, ElNaggar A, Liu M, Taylor JS, Ramondetta LM, Grinsfelder MO, Cobb LC, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims T, Sood AK, Ramirez RT, Lu KH, Jazaeri AA. Prognostic implications of detectable ovarian cancer minimal residual disease after frontline therapy by second look laparoscopy and circulating tumor DNA. Gynecol Oncol 190(Supplement 1):S19, 2024. e-Pub 2024.
12. Sood AK, Stur E, Fellman B, Conrads T, Abulez T, Chu Y, Bateman MW, Lee S, Yuan Y, Tran H, Conrads KA, Hood BL, Soliman PT, Fleming ND, Cobb L, Shafer A, Taylor J, Jazaeri A, Frumovitz M, Ramirez PT, Meyer LA, Alvarado T, Hull S, Lu KH, Mills GB, Wang L, Maxwell GL, Coleman RL, Westin SN. Molecular markers of response to enzalutamide-based therapy in advanced or recurrent endometrioid endometrial adenocarcinoma. Gynecol Oncol 190(Supplement 1):S20, 2024. e-Pub 2024.
13. Glassman D, Handley KF, Foster KF, Asare, Sims TT, Fleming ND, Lee S, Celestino J, Rangel KM, Sood AK. Does cancer appearance reflect genetic status? The relationship between the gross appearance of HGSOC and BRCA mutation status. Gynecol Oncol 190(Supplement 1):S227, 2024. e-Pub 2024.
14. Tarney CM, Fauceglia P, Ogata J, Oliver J, Abulez T, Hood BL, Conrads KA, Wong KK, Gershenson D, Lee S, Sood AK, Darcy KM, Phippen NT, Maxwell GL, Conrads TP, Bateman NW. Deep Quantitative Proteomics Identifies Elevated CA-125 in Low Compared to High Grade Serous Ovarian Carcinoma. Gynecol Oncol 190(Supplement 1):S220, 2024. e-Pub 2024.
15. Asare A, Fleming ND, Bateman N, Westin SN, Jazaeri AA, Yao J, Hajek RA, Celestino J, Fellman B, Rangel K, Sey E, Cronin SP, Phippen NT, Lu KH, Conrads, Maxwell GL, Lee S, Sood AK. Cracking the code: Understanding molecular signatures in ovarian cancer subgroups undergoing primary treatment. Gynecol Oncol 190(Supplement 1):S225, 2024. e-Pub 2024.
16. Asare A, Corvigno S, Fellman B, Fleming ND, Westin S, Lee S, Takahashi K, Sood AK. Finding the needle in the haystack: identifying risk of MDS/AML after PARP inhibitor treatment. Gynecol Oncol 190(Supplement 1):S44, 2024. e-Pub 2024.
17. Kinsely A, Dai Y, Lee S, Wilke RN, How J, Taylor Js FB, Ramondetta LM, Grinsfelder MO, Cobb LP, Boruta DM, Richarso G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims T, Sood AK, Ramirez PT, Lu K, and Jazaeri AA. Minimal residual disease as a prognostic marker and opportunity for intervention in advanced ovarian cancer. IGCS 2024 Annual Global Meeting, 2024.
18. Ogata J, Tarney C, Mhawech-Fauceglia P, Oliver J, Abulez T, Hood B, Conrads K, Rosalik K, Wong KK, Gershenson D, Lee S, Sood AK, Darcy K, Phippen N, Maxwell GL, Conrads T, Bateman NW. Deep Quantitative Proteomics Identifies Conserved Proteome Alterations in Low and High-Grade Serous Ovarian Cancers. American Society on Mass Spectrometry:318303, 2024.
19. Amma A, Corvigno S, Yao J, Zhao L, Fleming ND, Celestino J, Hajek RA, Kim MS, Legarreta AF, Lu KH, Takahashi K, Futreal PA, Jazaeri AA, Westin SN, Sood AK, Lee S. Landscape of clonal hematopoiesis prior to PARP inhibitor treatment in patients with ovarian cancer. Cancer Res 84(6_Supplement):5070, 2024. e-Pub 2024.
20. Corvigno S, Asare A, Yao J, Zhao L, Fleming N, Celestino J, Hajek RA, Goette NA, Rogers RT, Nguyen TV, Montoya RN, Lu KH, Jazaeri AA, Westin SN, Sood AK, Lee S. Identification of novel chemotherapy-related CHIP variations in patients with high-grade serous ovarian cancer. Cancer Res 84(6_Supplement):6407, 2024. e-Pub 2024.
21. Glassman D, Kim M, Spradlin M, Bada S, Bhattacharya P, Duta P, Kinsley CV, Foster KI, Bayraktar E, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, and Sood AK. Bridging bench to bedside: Unveiling and targeting resistance to anti-angiogenesis therapy. Felix Rutledge Society meeting, 2024.
22. Knisely A, Nitecki R, Dan M, Lee S, Fellman B, Rauh-Haina JA, Hillman RT, Taylor JS, Ramondett RM, Grinsfelder MO, Cobb LP, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sood AK, PRamirez PT, Lu KH, Wang L, and Jazaeri AA. Transforming frontline therapy in ovarian cancer by focusing on surgically documented minimal residual disease after frontline treatment. Gynecol Oncol 176(Supplement 1):S122-S123, 2023. e-Pub 2023.
23. Asare A, Corvigno S, Fellman B, Fleming N, Jazaeri AA, Westin SN, Lee S, Takahashi K, Sood AK. Diagramming the development of MDS/AML after treatment with PARP inhibitors. Gynecol Oncol 176(Supplement 1):S309-S310, 2023. e-Pub 2023.
24. Dutta P, Glassman D, Kim MS, Spradlin M, Bayraktar E, Stur E, Mangala L, Foster K, Lee S, Yap TA, Westin SN, Eberlin L, Sood AK, Bhattacharya P. Assessing Glutaminase Inhibition Treatment Response in Ovarian Cancer by Hyperpolarized Magnetic Resonance Spectroscopy. ISMRM, 2023.
25. Kim MS, Glassman D, Lankenau Ahumada A, Bayraktar E, Jennings NB, Joseph R, Lee S, Coleman R, Sood AK. Mechanisms of and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Res 83(7_Supplement):528, 2023. e-Pub 2023.
26. Stur E, Peng F, Teng B, Bayraktar E, Hu M, Corvigno S, Brown DJ, Lee S, Moore KN, Maxwell GL, Conrads TP, Fleming N, Navin N, Wang L, Sood AK. The dynamic immune behavior of primary and metastatic tumors of ovarian cancer. Cancer Res 83(7_Supplement):5782, 2023. e-Pub 2023.
27. Corvigno S, Yao J, Zhao L, Asare A, Celestino J, Hajek R, Kim MS, Arboleda Goette EA, Song P, Zhang QC, Song X, Mohammad MM, Shaw KR, Zhang J, Lu KH, Jazaeri AA, Westin SN, Sood AK, Lee S. Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancer. Cancer Res 83(7_Supplement):5473, 2023. e-Pub 2023.
28. Foster KI, Yao J, Zhao L, Asare A, Corvigno S, Lee S, Westin SN, Maxwell GL, Bateman NW, Conrads TR, Sood AA. Spatial Heterogeneity of Homologous Recombination Deficiency Status in High-Grade Serous Ovarian Cancer. Gynecol Oncol 117(Supplement), 2023. e-Pub 2023.
29. Asare A, Glassman D, Ajami NJ, Wong M, Foster K, Corvigno S, Afshar-Kharghan V, Fleming N, Lee S, Wargo J, Sood AK. Partners in crime: the relationship between the ovarian tumor microbiome and venous thromboembolism. Gynecol Oncol 176(Supplement):S293-S294, 2023. e-Pub 2023.
30. Laberiano-Fernandez C, Arrechedera C, Tamegnon A, Hajek RA, Celestino J, Wistuba J, Lee S, Jazaeri AA, Parra ER. Classification of the Tumor Microenvironment in the Ovarian Cancer Patient’s Tissues Could Drive a New Therapeutically Approach. USACAP:160, 2023.
31. Hinchcliff EM, Patel A, Fellman BM, Yuan Y, Chelvanambi M, Wargo J, Liu YY, Liu J, Lee S, Roszik J, Hillman RT, Westin SN, Sood AK, Soliman PT, Frumovitz MM, Shafer A, Meyer LA, Fleming ND, Gershenson DM, Vining DJ, Ganeshan D, Vining, Ganeshan D, Lu KH, Jazaeri AA. Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors. Gynecol Oncol 166(Supplement 1):S66, 2022. e-Pub 2022.
32. Glassman D, Bateman NW, Conrads TP, Lee S, Zhao L, Ivan C, Rangel K, Zhang J, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Yao J, Tan Y, Chen K, Sood AK. Why are thromboembolic events so common in ovarian cancer? An investigation of tumor-mediated molecular markers. Gynecol Oncol 166(Supplement 1):S129-S130, 2022. e-Pub 2022.
33. Foster KI, Shaw KR, Jin J, Westin SN, Yap TA, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Fleming ND, Sood AK. The devil you know: A population-level analysis of tumor-based next-generation sequencing of high-grade epithelial ovarian cancer. Gynecol Oncol 166(Supplement 1):S91-S92, 2022. e-Pub 2022.
34. Glassman D, Kim M, Badal S, Spradlin M, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin L, Nagrath D, Sood AK. What’s next after bevacizumab resistance? Targeting metabolic vulnerabilities in ovarian cancer. Gynecol Oncol 166(Supplement 1):S17-S18, 2022. e-Pub 2022.
35. Stur E, Corvigno S, Xu M, Chen K, Lee S, Liu J, Ricco E, Fleming ND, Kraushaar D, Zhang J, Sood AK. Spatially resolved transcriptomics to understand mechanisms of response to neoadjuvant chemotherapy. Cancer Res 82(12_Supplement):1175, 2022. e-Pub 2022.
36. Zhao L, Ma S, Fleming ND, Celestino J, Kim MS, Hajek RA, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Distinct molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer. Cancer Res 82(12_Supplement):5106, 2022. e-Pub 2022.
37. Nitecki R, Dang M, Lee S, Fellman B, Rauh-hain A Hillman T, Taylor JS, Ramondetta LM, Grinsfelder MO, Cobb LP, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sood AK, Tanguma C, Ramirez PT, Lu KH, Wang L, Jazaeri AA. Initial clinicopathologic and molecular characterization of minimal residual disease detected by second look laparoscopy after completion of frontline surgery and chemotherapy in patients with advanced stage ovarian cancer. Cancer Res 82(12_Supplement):4135, 2022. e-Pub 2022.
38. Glassman D, Kim MS, Dutta P, Kingsley C, Bayraktar E, Wu Y, Stur E, Mangala L, Foster K, Lee S, Yap TA, Westin SN, Bhattacharya PK, Sood AK. Hyperpolarized magnetic resonance spectroscopy assessment of the metabolic effects of glutaminase inhibitor therapy in an ovarian cancer model. Cancer Res 82(12_Supplement):2484, 2022. e-Pub 2022.
39. Lee S, Zhao L, Fleming ND, Celestino J, Hajek RA, Morgan MB, Liu Y, Westin SN, Jazaeri AA, Liu J, Zhang J, Futreal PA, Sood AK. Transcriptomic profiles of response to neoadjuvant chemotherapy in patients with high-grade serous ovarian cancer. Cancer Res 82(12_Supplement):5738, 2022. e-Pub 2022.
40. Corvigno S, Keating M, Spraldin ML, Badal S, Silva ID, Stur E, Darcy KM, Liu J, Fleming ND, Lee S, Eberlin LS, Sood AK. Metabolic profiling of pre- and post-treatment ovarian cancer tissues using in situ analyses. Cancer Res 82(12_Suppl):2331, 2022. e-Pub 2022.
41. Foster KI, Shaw KR, Jin J, Westin SN, Yap TA, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in ovarian cancer. J Clin Oncol:5545, 2022. e-Pub 2022.
42. Pereira I, Badal S, Corvingo S, Lin J, Lee S, Liu J, Sood AK, Eberlin AL. Desorption electrospray ionization mass spectrometry imaging to predict and understand response to neoadjuvant chemotherapy treatment of ovarian cancer. 65th ASMS:308491, 2021.
43. Glassman D, Lee S, Zhao L, Ivan C, Rangel K, Zhang J, Futreal PA, Fleming N, Afshar-Kharghan V, Sood AK. Messages from the genome: The genetic makeup of ovarian cancer and risks of venous thromboembolism. Gynecol Oncol 162(Supplement):S205-S206, 2021. e-Pub 2021.
44. Handley KF, Sims TT, Glassman D, Fleming ND, Lee S, Yao H, Yao J, Liu J, Bast RC, Westin SN, Celestino J, Rangel KM, Conrads TP, Maxwell GL, Ram PT, Sood AK. If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer. Gynecol Oncol 162(Supplement):S20-S21, 2021. e-Pub 2021.
45. Lee S, Zhao L, Little LD, Westin SN, Jazaeri AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T cell receptor diversity and integrative analyses of clinically defined high-grade serous ovarian cancer. Gynecol Oncol 162(Supplement):S138, 2021. e-Pub 2021.
46. Lee S, Zhao L, Celestino J, Hajek RA, Morgan MB, Kim MS, Westin SN, Jazaeri AA, Fleming ND, Liu J, Zhang J, Futreal PA, Sood AK. NF1 copy number alterations in clinically-defined subsets of high-grade serous ovarian cancers. Cancer Res 81(13_Supplment):2200, 2021. e-Pub 2021.
47. Rojas C, Bateman NW, Lee S, Fleming N, Hamilton CC, Conrads K, Wilson K, Loffredo J, Hood B, Zhou M, Darcy KM, Casablanca Y, Conrads TP, Sood AK, Maxwell AL. Excellent versus poor response to neoadjuvant chemotherapy is accompanied by unique proteome alterations in post versus pre-treatment HGSOC tumors. Gynecol Oncol 159(Supplement 1), 2020. e-Pub 2020.
48. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Jazaeri AA, Liu J, Burks JK, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer. Gynecol Oncol 159(Supplement 1):87, 2020. e-Pub 2020.
49. Westin SN, Lee S, Zhao L, Ying Y, Wu J, Hajek R, Sharafi S, Meyer L, Fleming ND, Jazaeri A, Coleman RL, Lu KH, Mills GB, Zhang J, Futreal PA, Sood AK. Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer. Cancer Res 80(16_Supplement):CT188, 2020. e-Pub 2020.
50. Lee S, Zhao L, Celestino J, Rangel KM, Hajek RA, Kim MS, Sharafi SE, Liu J, Fleming ND, Lu KH, Zhang J, Futreal PA, Mills GB, Westin SN, Sood AK, Jazaeri AA, Coleman RL. Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer. Cancer Res 80(16_Supplement):2941, 2020. e-Pub 2020.
51. Lee S, Zhao L, Westin SN, Bateman NW, Jazaeri AA, Fleming ND, Lu KH, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AA. High-depth whole genome sequencing of clinically-annotated high-grade serous ovarian cancers. Cancer Res 80(16_Supplement):2510, 2020. e-Pub 2020.
52. Badal SP, Sans M, Lee S, Corvigno S, Lin J, Keating M, Liu J, Sood AK, Eberlin AL. Identification of Metabolic Markers of Treatment Response and Adaptive Metabolic Changes in Ovarian Cancer Tissues using Mass Spectrometry Imaging. 64th ASMS:303909, 2020.
53. Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, Westin SN. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers. Gynecol Oncol 154(Supplement 1):1212, 2019. e-Pub 2019.
54. Labrie M, Kim TB, Ju Z, Lee S, Lu Y, Chen K, Mills GB, Westin SN. Window of opportunity trial: Assessing the adaptive response of HGSOC to PARPi for Informed combination therapies. Clin Cancer Res 25(22_Supplement):NT-098, 2019. e-Pub 2019.
55. Kendsersky ND, Ma H, Fang Y, Campell LG, Eng J, Lee S, Chin K, Westin SN, Mills AG. Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor. Clin Cancer Res 26(13):PR03, 2019. e-Pub 2019.
56. Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, Westin SN. Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers. Cancer Res 79(13_Supplement):2070, 2019. e-Pub 2019.
57. Kim MS, Ma S, Leuschner C, Lee S, Coleman RL, Sood AK. Targeting LHRH-R to improve immune response in ovarian cancer. Cancer Res 79(13_Supplement):3199, 2019. e-Pub 2019.
58. Labrie M, Fang Y, Ju Z, Litton JK, Kim TB, Salevieva K, Lee S, Vellano CP, Lu Y, Chen K, Celestino J, Liu J, Soliman PT, Frumovitz MM, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, Westin SN. Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers. MDACC Moonshot SAB meeting:12A, 2019.
59. Lopes IA, Kardosova M, Bianco TM, Arantes AQ, Silva CA, Scheucher PS, Tenen DG, Lee S, Rego EM, Welner RS, Alberich-Jorda M, Figueiredo-Pontes LL. C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells. Blood 132(Supplement 1):3721, 2018. e-Pub 2018.
60. Shah T, Chu Y, Lee S, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Ven C, Goldman SC, Lim MS, Hermiston M, Perkins SL, Cairo AM. Ibrutinib Significantly Enhances Programmed Cell Death and Overall Survival in Burkitt Lymphoma (BL) in NSG Xenografts: a pre-clinical study. Pediatr Blood Cancer:P310, 2017. e-Pub 2017.
61. Lee S, Yin C, Shah T, Ayello J, Morris E, Ven C, Cairo MS. Upregulation of DLEU1 significantly prolongs survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL. Cancer Res 76(Supplement):3838, 2016. e-Pub 2016.
62. Lee S, Yin C, Ayello J, Ven C, Cairo AM. Ruxolitinib, a Jak1/Jak2 inhibitor, significantly prolongs survival in both primary mediastinal B-cell lymphoma and Hodgkin lymphoma xenograft NSG mouse model: a potential targeted adjuvant therapy. Pediatr Blood Cancer 63(S2):S1-S65, 2016. e-Pub 2016.
63. Lee S, Yin C, Ayello J, Morris E, Ven C, Cairo AM. Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act as a Tumor Suppressor Gene in Pediatric BL. Blood 126(23):3656, 2015. e-Pub 2015.
64. Lee S, Yin C, Ayello J, Morris E, O’Connell T, Harrison L, Ven C, Barth M, Miles R, Galardy P, Goldman SC, Lim M, Hermiston M, McAllister-Lucas L, Giulino-Roth L, Perkins SL, Cairo AM. Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May Be a Potential Adjuvant Agent in the Treatment of BL. Blood 126(23):5117, 2015. e-Pub 2015.
65. Lee S, Yin C, Ayello J, Morris E, Harrison L, Ven C, Barth M, Miles R, Galardy P, Goldman SC, Lim M, Hermiston M, McAllister-Lucas L, Giulino-Roth L, Perkins SL, Cairo AM. Ibrutinib alone and in combination with dexamethasone and carfilzomib significantly inhibits cell proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL. Blood 126(23):4852, 2015. e-Pub 2015.
66. Lee S, Yin C, Ayello J, Morris E, Ven C, Cairo AM. Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-cell lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May Be a Potential Adjuvant Agent in the Treatment of PMBL and of HL. Blood 126(23):2732, 2015. e-Pub 2015.
67. Lee S, Yin C, Ayello J, Harrison L, Morris E, Ven C, Barth M, Miles R, Galardy P, Lim M, Hermiston M, McAllister-Lucas L, Roth LG, Perkins SL, Cairo MS. Ibrutinib alone and in combination with dexamethasone significantly inhibits cell proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib may be a potential targeted agent in combination therapy in patients with PMBL. Br J Haematol 171(S1):142, 2015. e-Pub 2015.
68. Lee S, Yin C, Ayello J, Ven C, Cairo MS. Ruxolitinib significantly prolonged survival in both a Primary Mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL) xenograft NSG mouse model: Ruxolitinib may be a potential adjuvant agent in the treatment of PMBL and HL. Br J Haematol 171(S1):174, 2015. e-Pub 2015.
69. Lee S, Yin C, O’Connell T, Barth M, Miles R, Ayello J, Harrison L, Ven C, Galardy P, Lim M, Hermiston M, McAllister-Lucas L, Roth LG, Perkins SL, Cairo AM. Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. Br J Haematol 171(S1):152, 2015. e-Pub 2015.
70. O’Connell T, Yin C, Harrison L, Ayello J, Ven C, Lee S, Cairo MS. Prolonged ibrutinib treatment of Burkitt lymphoma cells leads to ibrutinib resistance via changes in BTK and PLCgamma2 signaling. Br J Haematol 171(S1):172, 2015. e-Pub 2015.
71. Lee S, Yin C, Ayello J, Morris E, Ven C, Cairo MS. Regulation of DLEU1 expression significantly alters survival in rituximab-treated DLEU1 knockout and overexpressed human /Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in BL. Br J Haematol 171(S1):48, 2015. e-Pub 2015.
72. Yin C, Ayello J, Ven C, Cairo MS, Lee S. Overexpression of DLEU1 gene significantly induces programmed cell death in Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 may be a tumor suppressor gene in PMBL. Br J Haematol 171(S1):87, 2015. e-Pub 2015.
73. Lee S, Yin C, Ayello J, Morris E, Ven C, Cairo MS. DLEU1 significantly alters programmed cell death in chemoimmunotherapy treated TALENs-induced DLEU1 Burkitt lymphoma (BL) knockout: DLEU1 may act as a tumor suppressor gene in BL. Br J Haematol 171(S1):151, 2015. e-Pub 2015.
74. Lee S, Yin C, Ayello J, Ven C, Klein C, Cairo MS. Obinutuzumab (GA101) significantly inhibits cell proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future targeted agent in the treatment of PMBL. Br J Haematol 171(S1):141, 2015. e-Pub 2015.
75. Lee S, Yin C, O’Connell T, Ayello J, Ven C, Cairo MS. DLEU1 significantly alters programmed cell death in chemoimmunotherapy treated TALENs-induced DLEU1 knockout and DLEU1 overexpressing Burkitt Lymphoma (BL): DLEU1 may act as a tumor suppressor gene in pediatric BL. Cancer Res 75(15_Supplement):2077, 2015. e-Pub 2015.
76. Lee S, Yin C, O’Connell T, Barth M, Miles R, Ayello J, Harrison L, Ven C, Galardy P, Lim M, Hermiston M, McAllister-Lucas L, Roth LG, Perkins SL, Cairo MS. Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. Cancer Res 75(15_Supplement):2608, 2015. e-Pub 2015.
77. O’Connell T, Yin C, Harrison L, Ayello J, Ven C, Lee S, Cairo AM. Prolonged treatment of Burkitt lymphoma cells with ibrutinib leads to ibrutinib resistance via changes in BTK and PLCgamma2 signaling. Paul Woolf Pediatric Research Conference, 2015.
78. O’Connell T, Yin C, Harrison L, Ayello J, Ven C, Lee S, Cairo MS. Prolonged treatment of Burkitt lymphoma cells with ibrutinib lead to ibrutinib resistance via changes in the apoptotic mechanism. Graduate Student Research Forum, NYMC, 2015.
79. Yin C, Lee S, O’Connell T, Ayello J, Ven C, Cairo AM. Obinutuzumab (GA101) significantly inhibits cell proliferation and induces programmed cell death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future targeted agent for the treatment of PMBL. Blood 124(21):4492, 2014. e-Pub 2014.
80. Yin C, O’Connell T, Ayello J, Ven C, Lee S, Cairo MS. Obinutuzumab (GA101) significantly induces antiproliferative effects and programmed cell death, and significantly downregulates cell signaling pathways in primary mediastinal B-cell lymphoma (PMBL): Obinutuzumab may be a future potential targeted agent for treatment of PMBL. Cancer Res 74(19_Supplement):3096, 2014. e-Pub 2014.
81. Lee S, Yin C, O’Connell T, Ayello J, Ven C, Cairo MS. Transcription Activator-Like Effector Nucleases (TALENs) mediated silencing of Bruton’s tyrosine Kinase (BTK) inhibits phosphorylation of Erk in Burkitt lymphoma. Cancer Res 74(19_Supplement):3112, 2014. e-Pub 2014.
82. Lee S, Yin C, Ayello J, Ven C, Cairo AM. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (CAS) system mediated endogenous CD19 gene knockout model in Burkitt Lymphoma. Cancer Res 74(19_Supplement):3617, 2014. e-Pub 2014.
83. O’Connell T, Yin C, Barth M, Miles R, Ayello J, Harrison L, Ven C, Galardy P, Lim M, Hermiston M, McAllister-Lucas L, Roth LG, Perkins S, Lee S, Cairo AM. Ibrutinib significantly alters cell proliferation and apoptosis in BL and PMBL: Ibrutinib may be a potential adjuvant therapy in the treatment of BL and/or PMBL. Pediatr Blood Cancer 61(S2):139, 2014. e-Pub 2014.
84. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo AM. Obinutuzumab, a novel, anti-CD20 targeted monoclonal antibody, induces significant anti-proliferative and apoptotic effects, and significantly modifies cell signaling pathways in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future potential targeted agent for treatment of PMBL. The 4th Paul Woolf Research Conference, 2014.
85. Yin C, O’Connell T, Barth M, Miles R, Ayello J, Harrison L, Ven C, Galardy P, Lim M, Hermiston M, McAllister-Lucas L, Roth LG, Perkins S, Lee S, Cairo MS. Ibrutinib, a selective and covalent inhibitor of Bruton’s tyrosine kinase, significantly inhibits cell proliferation and induces apoptosis in Primary Mediastinal B-Cell lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL. ASH meeting on Lymphoma Biology:66734, 2014.
86. O’Connell T, Yin C, Barth M, Miles R, Ayello J, Harrison L, Ven C, Galardy P, Lim M, Hermiston M, McAllister-Lucas L, Roth LG, Perkins S, Lee S, Cairo MS. Ibrutinib significantly alters cell proliferation and programmed cell death in Burkitt lymphoma (BL): Ibrutinib may be a potential adjuvant agent in the treatment of BL. ASH meeting on Lymphoma Biology, 2014.
87. Lee S, Yin C, O’Connell T, Ayello J, Ven C, Cairo AM. Down-regulation of DLEU1 Significantly Inhibits Programmed Cell Death in Rituximab and Cyclophosphamide Treated TALENs-Mediated DLEU1 Knockout Burkitt Lymphoma (BL): DLEU1 may act as a tumor suppressor gene in pediatric BL. ASH meeting on Lymphoma Biology:66633, 2014.
88. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo MS. Ibrutinib (PCI-32765), a selective and covalent inhibitor of burton’s tyrosine kinase, significantly inhibits cell proliferation and enhance programmed cell death in Burkitt lymphoma (BL): Ibrutinib may be a potential therapeutic agent for treatment of BL. Graduate Student Research Forum, NYMC, 2014.
89. Lee S, Yin C, Ayello J, Genualdi M, Ven C, Cairo AM. Transcription Activator like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model. Blood 122(21):4883, 2013. e-Pub 2013.
90. Yin C, Chung TH, Ayello J, Park TH, Ven C, Cairo MS, Lee S. Overexpression of Deleted in Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 may be a tumor suppressor gene in a subset of patients with PMBL. Blood 122(21):3852, 2013. e-Pub 2013.
91. Yin C, O’Connell T, Ayello J, Ven C, Lee S, Cairo AM. Obinutuzumab (GA101), a novel type II glycoengineered CD20 antibody, significantly induced programmed cell death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab may be a future potential targeted agent for the treatment of PMBL. Blood 122(21):5146, 2013. e-Pub 2013.
92. Lee S, Yin C, Ayello J, O’Connell T, Ven C, Muniz M, Barth MJ, Cairo AM. Exogenous Overexpression of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells to RTX Induced Apoptosis. Blood 122(21):2503, 2013. e-Pub 2013.
93. Pais F, Lee S, Rodic V, Barth MJ, Cairo MS, Hermiston M, Miles AR. Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion of MIR17HG in Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. Blood 122(21):243, 2013. e-Pub 2013.
94. Lee S, Yin C, O’Connell T, Ayello J, Ven C, Cairo AM. Sequence-specific TALENS-induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases phosphorylation of AKT and IkBa in Pediatric Burkitt Lymphoma (PBL): DLEU1 may act as a Tumor Suppressor Gene in PBL. Blood 122(21):1279, 2013. e-Pub 2013.
95. Yin C, Lee S, Ayello J, Ven C, Cairo AM. Ruxolitinib, a JAK1/JAK2 inhibitor, inhibits cell proliferation and induces apoptosis in Hodgkin Lymphoma (HL) and Primary Mediastinal B-cell Lymphoma (PMBL). Pediatr Blood Cancer 60(S3):264, 2013. e-Pub 2013.
96. Lee S, Yin C, Ayello J, Ven C, Cairo AM. Transcription activator-like effector nucleases (TALENS) mediated DLEU1 Gene disruption suppresses apoptosis in Pediatric Burkitt Lymphoma (PBL): DLEU1 maybe a tumor suppressor gene in PBL. Pediatr Blood Cancer 60(S3):S264, 2013. e-Pub 2013.
97. Madris BD, Yin C, Ayello J, Ven C, Lee S, Cairo MS. Transcription activator-like effector nucleases mediated DLEU1 gene knockdown suppresses apoptosis in Burkitt’s lymphoma. The Pediatric Academic Societies Annual meeting, 2013.
98. Yong KJ, Gao C, Lim J, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Lee S, Ravikumar S, Sivastava S, Tian X, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Stem cell factor SALL4 as a prognostic marker and therapeutic target for the aggressive progenitor-like subgroup of hepatocellular carcinoma. APASL Liver Week, Singapore, 2013.
99. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo AM. DLEU1 knockout by Transcription Activator-Like Effector Nuclease (TALENs) inhibits Apoptosis in Pediatric Burkitt Lymphoma (PBL): DLEU1 may serve as a tumor suppressor gene (or mechanism) in PBL. The Eastern Society for Pediatric Research (SPR) Annual Meeting, 2013.
100. Madris BD, Yin C, Ayello J, Ven C, Lee S, Cairo MS. Transcription activator-like effector nucleases mediated DLEU1 gene knockdown suppresses apoptosis in Burkitt’s lymphoma. The Eastern Society for Pediatric Research (SPR) Annual Meeting, 2013.
101. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo AM. DLEU1 Knockout by Transcription Activator-Like Effector Nucleases (TALENs) Inhibits Programmed Cell Death in Pediatric Burkitt Lymphoma (PBL) Indicating Its Role as a Potential Tumor Suppressor Gene. 50th GSBMS, New York Medical College, 2013.
102. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo AM. DLEU1 knockout by Transcription Activator-Like Effector Nuclease (TALENs) inhibits Apoptosis in Pediatric Burkitt Lymphoma (PBL): DLEU1 may serve as a tumor suppressor gene (or mechanism) in PBL. The Pediatric Academic Societies (PAS) Annual meeting, 2013.
103. Lee S, Yin C, O’Connell T, Ayello J, Ven C, Cairo AM. Sequence-specific TALENS-induced endogenous DLEU1 knockout significantly inhibits chemotherapy-induced programmed cell death in Pediatric Burkitt Lymphoma (PBL): DLEU1 may act as a Tumor Suppressor Gene in PBL. The 3rd Pediatric Research symposium, 2013.
104. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo AM. Obinutuzumab, a novel type II glycoengineered CD20 antibody induced programmed cell death in Primary Mediastinal B-cell Lymphoma (PMBL) cell: Obinutuzumab may be a future potential targeted agent for the treatment of PMBL. The 3rd Paul Woolf Research conference, 2013.
105. O’Connell T, Yin C, Ayello J, Ven C, Lee S, Cairo AM. Transcription activator-like effector nucleases (TALENs) induced DLEU1 gene knockout inhibitor programmed cell death in pediatric Burkitt Lymphoma (PBL): DLEU1 maybe a tumor suppressor gene in PBL. The 3rd Paul Woolf Research conference, 2013.
106. Yin C, Lee S, Ayello J, Ven C, Pao J, Mulvey E, Cairo MS. JAK1/JAK2 inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-cell Lymphomas (PMBL). Blood 120(21):4886, 2012. e-Pub 2012.
107. Lee S, Yin C, Ayello J, Ven C, Biggar CP, Kwang HT, Mulvey E, Pao J, Cairo MS. Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL). Blood 120(21):2654, 2012. e-Pub 2012.
108. Lee S, Yin C, Ayello J, Ven C, Kwang HT, Biggar CP, Pao J, Mulvey E, Cairo MS. TALENS-Mediated DLEU1 Gene Silencing in Burkitt Lymphoma (BL): Implication of lncRNA DLEU1 Gene as a Potential Tumor Suppressor Gene in BL. Blood 120(21):2403, 2012. e-Pub 2012.
109. Lee S, Yin C, Ayello J, Ven C, Kwang HT, Biggar CP, Cairo MS. DLEU1 TALENS-Mediated Loss of Function in Burkitt Lymphoma (BL) Raji Cells: Implication of lncRNA DLEU1 Gene as a Tumor Suppressor Gene. Br J Haematol 159(S1):54, 2012. e-Pub 2012.
110. Lee S, Yin C, Ayello J, Ven C, Kwang HT, Biggar CP, Cairo MS. Silencing of Long Non-Coding RNA DLEU1 Gene by Transcription Activator-like Effector Nucleases (TALENS) in Burkitt Lymphoma Cells. Br J Haematol 159(S1):54, 2012. e-Pub 2012.
111. Yin C, Lee S, Ayello J, Ven C, Cairo MS. Inhibitory effect of Ruxolitinib (JAK2 inhibitor) on JAK2 signaling, proliferation and induction of apoptosis Hodgkin (HL) and primary mediastinal B-cell (PMBL) adolescent and young adult (ANA) lymphomas. Br J Haematol 159(S1):54, 2012. e-Pub 2012.
112. Yong KJ, Gao C, Lim J, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Lee S, Srivastava S, Tian X, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Stem Cell Factor Sall4 As A Prognostic Marker And Therapeutic Target For Advanced Hepatocellular Carcinoma. The Sixth Annual International Liver Cancer Association, 2012.
113. Lee S, Day NS, Ayello J, Ven C, Harrison A, Muniz M, Cairo AM. Long non-coding RNA DLEU1 gene knockdown with cyclophosphamide and/or rituximab induced apoptosis in pediatric Burkitt lymphoma (BL); Implication DLEU1 as a tumor suppressor gene. 1st Annual Assistant Professor Research Symposium, NYMC, 2012.
114. Lee S, Yin C, Ayello J, Ven C, Madris BD, Kwang HT, Biggar CP, Pao J, Mulvey E, Cairo AM. Transcription activator-like effector nucleases Mediated DLEU1 Gene Knock down in Raji Burkitt Lymphoma cells: Implication of a Potential Tumor Suppressor Gene in Burkitt Lymphoma. 2nd Annual Assistant Professor PRS, NYMC, 2012.
115. Yong KJ, Kawasaki A, Lee S, Yan B, Yang H, Ong CW, Srivastava S, Dimitrov T, Gao C, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Re-activation of the stem cell factor SALL4 and its role in hepatocellular carcinoma:P-27, 2011.
116. Yong KJ, Kawasaki A, Lee S, Yan B, Yang H, Ong CW, Srivastava S, Dimitrov T, Gao C, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Re-activation of the stem cell factor SALL4 and its role in hepatocellular carcinoma. Frontier Cancer Science of Singapore, 2011.
117. Ravikumar S, Yada S, Lai YS, Tenen DG, Lee S. Regulation of human Sall4 gene in normal and cancer states. Frontiers in Cancer Science of Singapore:P20, 2010.
118. Ebralidze AK, Ruscio A, Lee S, O’Brien KB, Tenen DG. Epigenetic Control of C/EBPa by Distant Synergic Regulatory Elements. Blood 114(22):1470, 2009. e-Pub 2009.
119. Lee S, AK Ebralidze AK, Ruscio A, Liew LM, O’Brien KB, Koschmieder S, Tenen DG. Characterization of the Distal Elements mediating transcriptional regulation of C/EBPa. Frontiers in Cancer Science of Singapore:P27, 2009.
120. Zhou YD, Lee S, Jin Z, Wright M, Anderson MP. Arrested developmental down-regulation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. The 38th annual meeting of the Society for Neuroscience, 2008.
121. Zhou YD, Lee S, Anderson MP. Temporal lobe epilepsy-related protein Lgi1 regulates hipppocampal perforant pathway synaptic transmission by reducing the probability of transmitter release. The 37th annual meeting of the Society for Neuroscience, 2007.
122. Anderson MP, Zhou YD, Lee S. Temporal lobe epilepsy-related protein Lgi1 regulates hippocampal perforant pathway glutamatergic synaptic transmission. The 61st annual meeting of American Epilepsy society, 2007.
123. Anderson MP, Zhou YD, Lee S. Effects of the human autosomal dominant lateral temporal lobe epilepsy gene LGI1 on the hippocampal dentate gyrus. Curing Epilepsy, 2007.
124. Atefy R, Lee S, Mochizuki T, Scammell TE, Schomer DL, Anderson MP. Chronic EEG Recordings in a Mouse Model of Human Autosomal Dominant Lateral Temporal Lobe Epilepsy. 60th Annual Meeting of the American Epilepsy Society, 2006.
125. Kasten M, Lee S, Anderson MP. Auditory thalamus hyperexcitability in a mouse model of human autosomal dominant lateral temporal lobe epilepsy. Epilepsia 47:280, 2006. e-Pub 2006.
126. Lee S, Anderson MP. Defining the protein complex associated with T-type Ca2+ channel Cav3.1 using epitope-tagged CACNA1G transgenic mice. The 35th society for neuroscience annual meeting, 2005.
127. Lee S, Andrieu C, Pouchkine V, Auclair J, Salaun B, Cahir-McFarland E, Kobayashi R, Mosialos G, Kieff E, Sylla BS. The RasGAP-associated Protein p62dok1 (Dok1) Is a Substrate for IKKβ. Keystone Meeting, 2002.
128. Sang BC, Ryoo SH, Lee S. Molecular genetic characteristic of the k-casein and beta lactoglobulin genes in Korea cattle. Proceedings of the 9th Annual Congress of the Asian-Australasian Association of Animal Production Societies, 2000.
129. Lee S, Sang BC, Kim SK, Park YJ. The Association of Genetic Polymorphisms of the BoLA-DRB3 Gene with Economic Traits in Cattle. Proceedings of the 9th Annual Congress of Animal Sciences and Technology:PA20066, 2000.
130. Lee S, Sang BC. Association of Microsatellite Polymorphisms of BoLA-DRB3 intron2 with Economic Traits in Holstein and Korean Cattle. Proceedings of the 9th Annual Congress of Animal Sciences and Technology, 2000.
131. Sang BC, Lee S, Kim JA, Han SW. The Genetic Characteristics of β-casein Gene using PCR-RFLP in Korean Native Goat. Proceedings of the 9th Annual Congress of Animal Sciences and Technology:PA20069, 2000.
132. Lee S, Sang BC, Kim SK, Park YJ. The Genetic Polymorphisms of the BoLA-DYA Gene in Cattle. Proceedings of the 9th Annual Congress of Animal Sciences and Technology, 2000.
133. Jeon BS, Lee S, Song CE, Choi SB, Ahn BS, Kim JS, Son DS, Ryoo SH, Kim SK, Sang BC. Association of the Resistance Gene for Bovine Leukemia Virus (BLV) in Bovine Lymphocyte Antigen DRB3 (BoLA-DRB3) with Milk Production traits in Holstein. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99063, 1999.
134. Jin HJ, Lee S, Lee HK, Park MK, Son DS, Kim MG, Kim TH, Yang BK, Kim JI, Sang BC, Kim SK. Identification of Microsatellite for Economic Traits in Pig. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99071, 1999.
135. Ryoo SH, Sang BC, Ryoo SR, Lee TH, Lee S, Ryoo DY. The Analysis of β-lactoglobulin and κ-casein cDNA in Korean Cattle and Holstein. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
136. Lee S, Sang BC, Kim HB, Kim HS, Jin HJ, Ryoo SH, Kim SK, Park YJ, Lee KD. The Genetic Characterization and Polymorphism of Growth Hormone Releasing Hormone (GHRH) Gene by Direct Sequencing Method in Cattle. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99064, 1999.
137. Ryoo SH, Sang BC, Ryoo SR, Lee TH, Lee S, Ryoo DY. The Analysis of β-lactoglobulin and κ-casein gene promoter region in Korean Cattle and Holstein. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
138. Kim HB, Kim HS, Lee S, Kim TH, Hong YH, Park NH, Jung JI. The Study on the Relation Test between Economic Traits and Microsatellite locus by Comparative linkage map. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
139. Kim HS, Kim CD, Lee S, Kim HB, Park EW, Sang BD, Cheong IC. A polymorphism study of chicken prolactin and prolactin-receptor gene related to broodiness. Proceedings of the 8th Annual Congress of Animal Sciences and Technology, 1999.
140. Kim TH, Yoon DH, Seo KS, Lee YK, Cheong IC, Son SK, Lee S. Genetic characterization of pig breeds using microsatellite DNA markers. Proceedings of the 8th Annual Congress of Animal Sciences and Technology:P99014, 1998.
141. Jin HY, Cho CY, Lee HK, Jang HS, Lee S, Choi CH, Sang BD, Son DS, Chung YH, Yamamoto Y. Analysis of Biochemical Genetic Polymorphisms in Korean Native Chicken and Foreign Breeds. The 8th World Conference on Animal Production Presentation:PG2-21, 1998.
142. Ryoo SH, Sang BC, Han SW, Lee S, Jeon BS, Kim JH. Association of the genetic polymorphisms of κ-casein and β-lactoglobulin with preweaning body weights of Korean cattle using PCR-RFLP. The 8th World Conference on Animal Production:PG2-24, 1998.
143. Lee HK, Jin HJ, Lee S, Kim TH, Na SH, Lee DW, Heo TY, Son DS, Choi JS, Park MG. Study on the characterization of PSS (Porcine Stress Syndrome) gene expression. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:A9717, 1997.
144. Jin HJ, Lee HK, Lee S, Na SH, Kim HS, Cho CY, Ryoo IS, Han KJ, Kim JI. The Effect of Specific Genetic Markers on the Economic Traits of Bulls in Holstein. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:PA97031, 1997.
145. Lee S, Jin HJ, Na SH, Cho CY, Jeon KJ, Lee HK, Seo KH, Kim JS. The study on the characterization of genotypes of Specific gene in Korean Cattle and Holstein using PCR-RFLP. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:A9713, 1997.
146. Ryoo SH, Sang BC, Lee S, Kang HB, Lee CS. Association between Genetic Polymorphism of Blood Protein and Meat Production Traits in Korean Native Goat. Proceedings of the 7th Annual Congress of Animal Sciences and Technology:A9711, 1997.
147. Lee S, Sang BC, Han SW, Kwon I, Sung CG. The Analysis of Genetic Diversity between Korean Cattle Meat and Imported Meat. Proceeding of the 57th Congress of Food Sciences:PA-25, 1996.
148. Lee S, Sang BC, Kwon I, Sung CG. The Analysis of Genetic Similarity between Korean cattle and Charolais using RAPD technique. Proceedings of the 6th Annual Congress of Animal Sciences and Technology:PA9614, 1996.
149. Choi IH, Lee S, Jang HJ, Lee CS, Sang BC, Oh HR. Verification of practicality of marker gene for identification of Korean cattle. Korean Society for Food Science of Animal Resources:121, 1996. e-Pub 1996.